{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["anti-inflammatory effects", "seborrheic dermatitis", "skin disorders", "topical statin"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "31118730", "DateRevised": {"Year": "2020", "Month": "10", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "04", "Day": "29"}], "Language": ["eng"], "ELocationID": ["10.2147/CCID.S196412"], "Journal": {"ISSN": "1178-7015", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2019"}}, "Title": "Clinical, cosmetic and investigational dermatology", "ISOAbbreviation": "Clin Cosmet Investig Dermatol"}, "ArticleTitle": "Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis.", "Pagination": {"StartPage": "267", "EndPage": "275", "MedlinePgn": "267-275"}, "Abstract": {"AbstractText": ["<b>Purpose:</b> Seborrheic dermatitis (SD) is a chronic inflammatory skin disorder that mainly affects areas rich in sebaceous glands, such as the scalp. Although the exact cause of SD is not clearly understood, it seems that skin colonization with Malassezia fungus and the inflammatory responses of the immune system to this fungus play an important role in the pathology of SD. Recently a growing body of evidence has shown anti-inflammatory and anti-fungal effects of statins. Thus, this study aimed to evaluate the efficacy of topical atorvastatin in the treatment of scalp SD. <b>Patients and methods:</b> In this double-blind, clinical trial, 86 patients with mild-to-moderate scalp SD were divided into either atorvastatin (n=45) or betamethasone groups (n=41) by block randomization method. In addition to the ketoconazole 2% shampoo (3 times per week), the atorvastatin group received atorvastatin 5% lotion and the betamethasone group received betamethasone 0.1% lotion daily for 4 weeks. The SD severity of each patient was determined by Symptom Scale of Seborrheic Dermatitis (SSSD) at baseline and 4 weeks after treatment. Also, the patient's satisfaction of the treatment and adverse effects were investigated through individual reporting. <b>Results:</b> After 4 weeks of treatment, the score of SD severity decreased significantly in both groups, while changes of SSSD score from baseline to the fourth week of treatment were comparable in the two groups (<i>P</i>-value=0.476). Regarding patient's satisfaction of the treatment, results demonstrated the non-inferiority of atorvastatin as compared to betamethasone. Topical atorvastatin was also well-tolerated in almost all patients. <b>Conclusion:</b> Although preliminary, the results of the present study showed that topical atorvastatin has a comparable effect to topical betamethasone and can be considered as an alternative therapeutic modality in the treatment of scalp SD. However, these results need to be confirmed in future studies while taking into consideration the improvement of topical statin formulations."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Psoriasis Research Center, Department of Dermatology, Farshchian Hospital, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Sobhan", "ForeName": "Mohammadreza", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Gholampoor", "ForeName": "Ghazal", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants and Natural Products Research Center, Hamadan University of Medical Sciences, Hamadan, Iran."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Firozian", "ForeName": "Farzin", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Modeling of Noncommunicable Diseases Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Mohammadi", "ForeName": "Younes", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran."}], "LastName": "Mehrpooya", "ForeName": "Maryam", "Initials": "M"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Clin Cosmet Investig Dermatol", "NlmUniqueID": "101543449", "ISSNLinking": "1178-7015"}, "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Gary G. Optimizing treatment approaches in seborrheic dermatitis. J Clin Aesthet Dermatol. 2013;6(2):44.", "ArticleIdList": ["PMC3579488", "23441240"]}, {"Citation": "Gupta A, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18(1):13\u201326. doi:10.1111/jdv.2004.18.issue-1", "ArticleIdList": ["10.1111/jdv.2004.18.issue-1", "14678527"]}, {"Citation": "Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome: a clinicopathologic study. J Am Acad Dermatol. 1986;14(2):242\u2013248.", "ArticleIdList": ["2936776"]}, {"Citation": "Burton J, Pye R. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed). 1983;286(6372):1169\u20131170.", "ArticleIdList": ["PMC1547390", "6220754"]}, {"Citation": "Pech\u00e8re M, Krischer J, Remondat C, Bertrand C, Trellu L, Saurat JH. Malassezia spp carriage in patients with seborrheic dermatitis. J Dermatol. 1999;26(9):558\u2013561.", "ArticleIdList": ["10535248"]}, {"Citation": "Falk MHS, Linder MT, Johansson C, et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol. 2005;85(1):17\u201323. doi:10.1080/00015550410022276", "ArticleIdList": ["10.1080/00015550410022276", "15848985"]}, {"Citation": "Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G. Seborrhoeic dermatitis and pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144(3):549\u2013556.", "ArticleIdList": ["11260013"]}, {"Citation": "Riciputo R, Oliveri S, Micali G, Sapuppo A. Phospholipase activity in Malassezia furfur pathogenic strains: phospholipase\u2010Aktivit\u00e4t an patientenisolaten von Malassezia furfur. Mycoses. 1996;39(5\u20106):233\u2013235.", "ArticleIdList": ["8909036"]}, {"Citation": "Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest dermatol. 2001;116(5):769\u2013773. doi:10.1046/j.1523-1747.2001.01321.x", "ArticleIdList": ["10.1046/j.1523-1747.2001.01321.x", "11348468"]}, {"Citation": "Ballanger F, Tenaud I, Volteau C, Khammari A, Dr\u00e9no B. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res. 2008;300(5):215. doi:10.1007/s00403-007-0806-1", "ArticleIdList": ["10.1007/s00403-007-0806-1", "18330588"]}, {"Citation": "Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;(5):CD009446.", "ArticleIdList": ["PMC6483543", "24838779"]}, {"Citation": "Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments:: facts and controversies. Clin Dermatol. 2013;31(4):343\u2013351. doi:10.1016/j.clindermatol.2013.01.001", "ArticleIdList": ["10.1016/j.clindermatol.2013.01.001", "23806151"]}, {"Citation": "Soares RC, Zani MB, Arruda ACBB, de Arruda LHF, Paulino LC. Malassezia intra-specific diversity and potentially new species in the skin microbiota from Brazilian healthy subjects and seborrheic dermatitis patients. PLoS One. 2015;10(2):e0117921. doi:10.1371/journal.pone.0117921", "ArticleIdList": ["10.1371/journal.pone.0117921", "PMC4335070", "25695430"]}, {"Citation": "Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a cochrane review. JAMA dermatol. 2015;151(2):221\u2013222. doi:10.1001/jamadermatol.2014.3186", "ArticleIdList": ["10.1001/jamadermatol.2014.3186", "25629391"]}, {"Citation": "Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005;141(1):47\u201352. doi:10.1001/archderm.141.1.47", "ArticleIdList": ["10.1001/archderm.141.1.47", "15655141"]}, {"Citation": "Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29\u201338. doi:10.1056/NEJMoa042000", "ArticleIdList": ["10.1056/NEJMoa042000", "15635110"]}, {"Citation": "Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99(1):95\u2013112. doi:10.1016/S0163-7258(03)00055-X", "ArticleIdList": ["10.1016/S0163-7258(03)00055-X", "12804701"]}, {"Citation": "Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol. 2010;49(11):1235\u20131243. doi:10.1111/j.1365-4632.2010.04579.x", "ArticleIdList": ["10.1111/j.1365-4632.2010.04579.x", "20964647"]}, {"Citation": "Bergman PW, Bj\u00f6rkhem-Bergman L. Is there a role for statins in fungal infections? Expert Rev Anti Infect Ther. 2013;11(12):1391\u20131400. doi:10.1586/14787210.2014.856755", "ArticleIdList": ["10.1586/14787210.2014.856755", "24215244"]}, {"Citation": "Khurana S, Gupta S, Bhalla H, Nandwani S, Gupta V. Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. J Pharmacol Pharmacother. 2015;6(3):130. doi:10.4103/0976-500X.162011", "ArticleIdList": ["10.4103/0976-500X.162011", "PMC4544133", "26311995"]}, {"Citation": "Toker S, Gulcan E, Cayc\u0131 MK, Olgun EG, Erbilen E, \u00d6zay Y. Topical atorvastatin in the treatment of diabetic wounds. Am J Med Sci. 2009;338(3):201\u2013204. doi:10.1097/MAJ.0b013e3181aaf209", "ArticleIdList": ["10.1097/MAJ.0b013e3181aaf209", "19667969"]}, {"Citation": "Buechner SA. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 2014;25(3):226\u2013231. doi:10.3109/09546634.2013.782092", "ArticleIdList": ["10.3109/09546634.2013.782092", "23557492"]}, {"Citation": "Goldust M, Rezaee E, Raghifar R. Treatment of seborrheic dermatitis: comparison of sertaconazole 2% cream versus pimecrolimus 1% cream. Ir J Med Sci. 2013;182(4):703\u2013706. doi:10.1007/s11845-013-0960-8", "ArticleIdList": ["10.1007/s11845-013-0960-8", "23715821"]}, {"Citation": "Hay R. Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol. 2011;165:2\u20138. doi:10.1111/j.1365-2133.2011.10570.x", "ArticleIdList": ["10.1111/j.1365-2133.2011.10570.x", "21919896"]}, {"Citation": "McGinley KJ, Leyden JJ, Marples RR, Path M, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. 1975;64(6):401\u2013405.", "ArticleIdList": ["237965"]}, {"Citation": "Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol. 1990;23(1):82\u201386.", "ArticleIdList": ["1694869"]}, {"Citation": "Bergbrant IM, Johansson S, Robbins D, Scheynius A, Faergemann J, S\u00f6derstr\u00f6m T. An immunological study in patients with seborrhoeic dermatitis. Clin Exp Dermatol. 1991;16(5):331\u2013338.", "ArticleIdList": ["1838969"]}, {"Citation": "Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519\u20131530.", "ArticleIdList": ["PMC3394171", "22364136"]}, {"Citation": "Naseri M, Hadipour A, Sepaskhah M, Namazi M. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med. 2010;19(1):58\u201361.", "ArticleIdList": ["20232758"]}, {"Citation": "Faghihi T, Radfar M, Mehrabian Z, Ehsani AH, Hemami MR. Atorvastatin for the treatment of plaque\u2010type psoriasis. Pharmacotherapy. 2011;31(11):1045\u20131050. doi:10.1592/phco.31.11.1045", "ArticleIdList": ["10.1592/phco.31.11.1045", "22026392"]}, {"Citation": "Jacobi T, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol. 2003;149(6):1305\u20131306.", "ArticleIdList": ["14674922"]}, {"Citation": "Lanham M, Lebovic D, Domino S. Contemporary medical therapy for polycystic ovary syndrome. Int J Gynecol Obstet. 2006;95(3):236\u2013241. doi:10.1016/j.ijgo.2006.08.004", "ArticleIdList": ["10.1016/j.ijgo.2006.08.004", "17010975"]}, {"Citation": "Ahmadvand A, Yazdanfar A, Yasrebifar F, Mohammadi Y, Mahjub R, Mehrpooya M. Evaluating the effects of oral and topical simvastatin in the treatment of acne vulgaris: a double-blind, randomized, placebo-controlled clinical trial. Curr Clin Pharmacol. 2018;13(4):279\u2013283. doi:10.2174/1574884713666180821143545", "ArticleIdList": ["10.2174/1574884713666180821143545", "30129417"]}, {"Citation": "Bracht L, Caparroz\u2010Assef SM, Magon T, Ritter AMV, Cuman RKN, Bersani\u2010Amado CA. Topical anti\u2010inflammatory effect of hypocholesterolaemic drugs. J Pharm Pharmacol. 2011;63(7):971\u2013975. doi:10.1111/j.2042-7158.2011.01302.x", "ArticleIdList": ["10.1111/j.2042-7158.2011.01302.x", "21635264"]}, {"Citation": "Joshi R, Olver I, Keefe D, Marafioti T, Smith K. A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia. Support Care Cancer. 2007;15(9):1109\u20131112. doi:10.1007/s00520-007-0267-2", "ArticleIdList": ["10.1007/s00520-007-0267-2", "17516093"]}, {"Citation": "Otuki MF, Pietrovski EF, Cabrini DA. Topical simvastatin: preclinical evidence for a treatment of skin inflammatory conditions. J Dermatol Sci. 2006;44(1):45\u201347. doi:10.1016/j.jdermsci.2006.04.006", "ArticleIdList": ["10.1016/j.jdermsci.2006.04.006", "16759838"]}, {"Citation": "Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007;21(1):17\u201324. doi:10.1111/j.1468-3083.2006.01838.x", "ArticleIdList": ["10.1111/j.1468-3083.2006.01838.x", "17207162"]}, {"Citation": "Cabral ME, Figueroa LI, Fari\u00f1a JI. Synergistic antifungal activity of statin\u2013azole associations as witnessed by Saccharomyces cerevisiae-and Candida utilis-bioassays and ergosterol quantification. Rev Iberoam Micol. 2013;30(1):31\u201338. doi:10.1016/j.riam.2012.09.006", "ArticleIdList": ["10.1016/j.riam.2012.09.006", "23069981"]}, {"Citation": "Galg\u00f3czy L, Luk\u00e1cs G, Nyilasi I, Papp T, V\u00e1gv\u00f6lgyi C. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. Acta Biol Hung. 2010;61(3):356\u2013365. doi:10.1556/ABiol.61.2010.3.11", "ArticleIdList": ["10.1556/ABiol.61.2010.3.11", "20724281"]}]}], "History": [{"Year": "2018", "Month": "11", "Day": "29"}, {"Year": "2019", "Month": "3", "Day": "5"}, {"Year": "2019", "Month": "5", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "24", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "24", "Hour": "6", "Minute": "1"}, {"Year": "2019", "Month": "4", "Day": "29"}], "PublicationStatus": "epublish", "ArticleIdList": ["31118730", "PMC6503294", "10.2147/CCID.S196412", "196412"]}}]}